Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.0204498977505114 -0.016359918200409 0.00204498977505108 -0.0122699386503068
Stock impact report

Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (A...

ZIOPHARM Oncology Inc (ZIOP) 
Last ziopharm oncology inc earnings: 3/2 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ziopharm.com
Company Research Source: GlobeNewswire
- Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers- Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20mg veledimex cohort who received Controlled IL-12 as a single agent- Over expression of immune checkpoint biomarkers demonstrated- Abscopal anti-tumor effect documented in metastatic breast cancer- Data strongly support development of Controlled IL-12 platform in combination with immune checkpoint inhibitors BOSTON, June 04, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today presented clinical data showing the Company’s Controlled IL-12 platform as monotherapy achieved anti-tumor responses in patients with metastatic breast cancer (mBC) and patients with recurrent glioblastoma (rGBM) at the 2018 American Society of Clinical Oncology (ASCO) Annual Show less Read more
Impact Snapshot
Event Time:
ZIOP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ZIOP alerts
Opt-in for
ZIOP alerts

from News Quantified
Opt-in for
ZIOP alerts

from News Quantified